Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT05668936·Phase 1·INTERVENTIONAL

A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants

CotadutideOtherTerminated

Status

Terminated

Phase

Phase 1

Enrollment

31

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.

Full detailed description

This study will be a randomized, double-blind, placebo-controlled 3-arm parallel study with a nested crossover design for positive control with moxifloxacin administration in healthy male and female participants. Participants will be randomized to receive treatment with either cotadutide during the 13-week treatment period (Arm 1) or cotadutide-placebo (Arm 2). The cotadutide-placebo treatment arm will be further divided into 2 subgroups (Arms 2A and 2B), in a nested crossover design for only the placebo-treated participants. Participants will be randomized in a 2:1:1 ratio to Arm 1, Arm 2A, and Arm 2B. Approximately 80 participants will be randomized to have 64 evaluable participants in the study. Each participant will be involved in the study for approximately 22 weeks.

Interventions

Treatment arms and agents.

DRUG

Cotadutide

Participants will receive a subcutaneous injection of cotadutide.

DRUG

Cotadutide-placebo

Participants will receive a subcutaneous injection of cotadutide-placebo.

DRUG

Moxifloxacin

Participants will receive a single oral dose of Moxifloxacin film-coated tablet.

DRUG

Moxifloxacin-placebo

Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.

Timeline

From registration to results.

  1. First posted

    Dec 30, 2022

  2. Study start

    Jan 3, 2023

  3. Primary completion

    Mar 10, 2023

  4. Study completion

    Mar 10, 2023

  5. Results posted

    Not reported

  6. Registry updated

    Apr 5, 2023

Outcomes

What the study measures.

Primary outcomes

Time-matched change-from-baseline Fridericia's correction of QT interval (QTcF)

Time frame · Up to Day 92

Time-matched change-from-baseline QTcF after cotadutide administration compared with placebo will be assesed using a C-QTc interval analysis. The method that removes the HR dependence of the QT interval most efficiently will be chosen as the primary correction method and its corresponding change from baseline QTc will be the primary endpoint.

Secondary outcomes

Change from baseline in QTcF

Time frame · Up to Day 94

Change from baseline in QTcF after moxifloxacin administration compared with placebo will be assessed.

Change from baseline in Heart rate (HR)

Time frame · From Day 2 up to Day 92 or early discontinuation

The effect of cotadutide on HR will be assessed.

Change from baseline in PR interval

Time frame · From Day 2 up to Day 92 or early discontinuation

The effect of cotadutide on PR interval will be assessed.

Change from baseline in QRS interval

Time frame · From Day 2 up to Day 92 or early discontinuation

The effect of cotadutide on QRS will be assessed.

Number of participants with significant change in QTcF

Time frame · From Day 2 up to Day 92 or early discontinuation

The presence of categorical outliers for QTc after cotadutide administration will be assessed.

Number of participants with significant change in HR

Time frame · From Day 2 up to Day 92 or early discontinuation

The presence of categorical outliers for HR after cotadutide administration will be assessed.

Number of participants with significant change in PR interval

Time frame · From Day 2 up to Day 92 or early discontinuation

The presence of categorical outliers for PR after cotadutide administration will be assessed.

Number of participants with significant change in QRS interval

Time frame · From Day 2 up to Day 92 or early discontinuation

The presence of categorical outliers for QRS after cotadutide administration will be assessed.

Number of treatment-emergent changes in T-wave morphology

Time frame · From Day 2 up to Day 92 or early discontinuation

Morphological changes in the T-U complex after cotadutide administration will be investigated.

Number of treatment-emergent changes in U-waves presence

Time frame · From Day 2 up to Day 92 or early discontinuation

Morphological changes in the T-U complex after cotadutide administration will be investigated.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
55 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: * Healthy male and female participants of age 18 to 55 years. * Females must have a negative pregnancy test. * Have a Body Mass Index (BMI) of ≥ 18 and ≤ 29.9 kg/m\^2. Exclusion Criteria: * History or presence of any clinically significant disease or disorder. * History or presence of gastrointestinal, hepatic or renal disease, or any other condition (including gastrointestinal surgery) known to interfere with absorption, distribution, metabolism, or excretion of drugs. * History of acute or chronic pancreatitis. * Family history of sudden cardiac death before the age of 50 of a first-degree relative. * History of additional risk factors for Torsade de Pointes (eg, heart failure, clinically important bradycardia and electrolyte disturbances eg, hypokalemia, hypocalcemia, hypomagnesemia or family history of long QT syndrome). * History of neoplastic disease * Any clinically significant abnormalities in clinical chemistry, hematology, urinalysis results or vital signs. * Any clinically significant abnormalities in rhythm, conduction, or morphology of the 12-lead resting electrocardiogram (ECG). * Any positive result on screening for serum hepatitis B surface antigen OR anti-HBc antibody, indicative of active hepatitis B (ie, participants with positive anti-HBc antibody result are acceptable if anti HBc IgM antibodies are negative), hepatitis C antibody, and Human immunodeficiency virus (HIV) antibody. * Current smokers or those who have smoked or used nicotine products (including e-cigarettes). * Known or suspected history of alcohol or drug abuse or excessive intake of alcohol. * Use of drugs with enzyme-inducing properties such as St John's Wort. * Participant has a positive test result for SARS-CoV-2 RT-PCR during screening period or at baseline. * Participant has clinical signs and symptoms consistent with COVID-19 or a history of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).

Study locations

1 registered sites.

Germany. Showing up to 24 locations stored in the fast local snapshot.

Research Site

Berlin, Germany

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Cotadutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsCotadutide trial dashboard →